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Abstract
Schizophrenia is a devastating neuropsychiatric disorder with genetically complex traits. Genetic variants should explain a
considerable portion of the risk for schizophrenia, and genome-wide association study (GWAS) is a potentially powerful tool
for identifying the risk variants that underlie the disease. Here, we report the results of a three-stage analysis of three
independent cohorts consisting of a total of 2,535 samples from Japanese and Chinese populations for searching
schizophrenia susceptibility genes using a GWAS approach. Firstly, we examined 115,770 single nucleotide polymorphisms
(SNPs) in 120 patient-parents trio samples from Japanese schizophrenia pedigrees. In stage II, we evaluated 1,632 SNPs
(1,159 SNPs of p,0.01 and 473 SNPs of p,0.05 that located in previously reported linkage regions). The second sample
consisted of 1,012 case-control samples of Japanese origin. The most significant p value was obtained for the SNP in the
ELAVL2 [(embryonic lethal, abnormal vision, Drosophila)-like 2] gene located on 9p21.3 (p=0.00087). In stage III, we
scrutinized the ELAVL2 gene by genotyping gene-centric tagSNPs in the third sample set of 293 family samples (1,163
individuals) of Chinese descent and the SNP in the gene showed a nominal association with schizophrenia in Chinese
population (p=0.026). The current data in Asian population would be helpful for deciphering ethnic diversity of
schizophrenia etiology.
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Introduction
Schizophrenia is a debilitating mental disorder characterized by
psychotic manifestations including hallucinations, delusions, and
cognitive deficits. Despite the high heritability of the disease
estimated at up to 80%, key molecules and/or molecular pathways
underlying the disease are still elusive. Candidate gene-based
analyses have an inherent limitation, that is, we do not know the
precise pathophysiological basis for the disease. However, through
the rapid development of genotyping technology, it has become
feasible to genotype hundreds of thousands of single nucleotide
polymorphisms (SNPs) covering the whole human genome. A shift
toward genome-wide association study (GWAS) from a gene-based
approach is accelerated. To date, a number of GWASs of
psychiatric disorders, including schizophrenia, have been reported
[1,2,3,4,5,6,7]. These have produced substantial evidence for the
association of the disease with specific risk loci. For instance,
O’Donovan et al. reported the evidence for association around
ZNF804A (p=1.61610
27) [2]. However, the protein encoded by
ZNF804A is uncharacterized and its function is unknown. No
functional candidate genes that stemmed from current understand-
ing of schizophrenia pathophysiology surpassed the genome-wide
significance level in that study. It is also noteworthy that many
GWASs so far have potentially missed the true association of the
genes withsmall effect, because of a stringent threshold. Conversely,
a liberal threshold requires follow-up studies to eliminate false
positives from genuine associations. Therefore, a simple procedure
for overcoming this problem is the use of a multistage screening
approach, using a modest threshold in each stage. In addition, case-
control design is liable to population stratification, which can cause
spurious associations. To eliminate false positives due to population
stratification and other confounding factors, the transmission
disequilibrium test (TDT) design that uses patients and their parents
(trios) is preferable as an alternative approach.
In this study, starting from a whole genome association survey of
trio families, we carried out a staged association study for
schizophrenia by analyzing three sets of samples, two from
Japanese cohort and one from Chinese population, which is
ethnically close to Japanese. All three sets of our samples showed a
nominally significant association with a SNP on the ELAVL2 gene.
This Asian GWAS of schizophrenia is hoped to provide a broader
view of the genetic basis of schizophrenia, because schizophrenia
GWASs to date are much accumulated in European descent.
Results
Stage I: GWAS of Japanese trio samples
Because of concerns regarding population stratification and
other unknown confounding factors, we performed the first-stage
screening restricted to pedigree trio samples comprising 120
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6families, each consisting of a patient with schizophrenia and their
parents. All the subjects were Japanese and diagnosis of
schizophrenia was carried out by at least two experienced
psychiatrists according to DSM-IV criteria, on the basis of
interview and medical records.
The trios were initially genotyped using Affymetrix GeneChip
Mapping 100 K Arrays. Out of a total of 115,770 SNPs, 97,963
SNPs were successfully genotyped. The rest, 17,807 SNPs, were
nonpolymorphic in the Japanese population or failed at the
genotyping stage. They were excluded from further analyses. We
ranked genotyped SNPs on the basis of strength of association
using the allelic association test. Nominally significant results were
detected for 1,159 SNPs (p,0.01).
Genotyping data yielded an average call rate of 96.6%, and
apparent inheritance errors in trio samples were detected in
,0.2% of all SNPs. A quantile-quantile (QQ) plot for association
results is provided in Figure 1. The group of SNPs that slightly
deviated from a diagonal straight line in the QQ plot are
considered to reflect SNPs with weak genetic effects, and from the
plot, it seems that there is not gross inflation of false-positive results
derived from genotyping errors.
The most significant p value was obtained for marker rs2174623
at 4q28.1 (p=6.11610
26), followed by markers rs883955 at Xq24
(p=7.10610
26) and rs10499585 at 7p15.1 (p=3.14610
25).
However, no human reference gene was located at these regions.
P values for the TDT analyses of schizophrenia trios for all 97,963
SNPs are shown in a Manhattan plot (Figure 2).
Stage II: Replication in Japanese case-control samples
We selected 1,632 SNPs from the first-stage screening [1,159
SNPs of p,0.01, and 473 SNPs of p,0.05 located in previously
reported linkage regions [8,9]]. In the second-stage analysis, we
have taken advantage of an affordable multiplex genotyping
platform (Illumina Bead Array). The second sample consisted of
506 patients with schizophrenia and 506 age- and sex-matched
controls of Japanese origin. Control subjects were recruited from
hospital staff and volunteers who had no family history of
psychoses. They showed no current or past evidence of psychoses,
during brief interviews by expert psychiatrists. In this experiment,
120 SNPs have dropped owing to the low designability of target
SNPs and 40 SNPs could not be genotyped. Accordingly, 1,472
SNPs were successfully genotyped in an independent Japanese
case-control sample. Sixty-nine SNPs located on autosomes and 17
SNPs located on chromosome X showed a nominal significance of
p,0.05 (Tables S1, S2). It may be reasonable not to declare a
compelling association regarding these SNPs because of multiple
testing, therefore, the interpretation of data must be made with
caution. The top 20 SNPs are listed in Table 1. The most
significant p value in the second-stage analysis was obtained for the
SNP in the ELAVL2 [(embryonic lethal, abnormal vision,
Drosophila)-like 2] gene located on 9p21.3 (p=0.00087).
Stage III: Replication in Chinese family samples collected
by NIMH
Japanese and Chinese are genetically close, but apparently
different populations. In addition, the gene-based approach
provides more information than single-SNP analysis, because a
high-density mapping could capture the potential risk-conferring
variations, which is difficult by examining sparse-density SNPs on
the GeneChip.
Accordingly, to confirm association signals in a gene-based
manner, we performed a follow-up study of the ELAVL2 gene whose
SNP showed the most compelling association in the case-control
study using Japanese population, by densely genotyping 293 pedigree
samples (284 quad and 9 trio samples, consisting of 1,163 family
members) from Chinese population. We analyzed 56 tagSNPs
located in and around the ELAVL2 gene. This gene has not been
reported to be genetically associated with schizophrenia to date.
As shown in Figure 3, single marker analysis in the third set
showed a nominally significant association with four SNPs on the
gene (lowest p=0.026). Three SNPs are clustered in the intron 1 of
the gene. They lose significance when conservative Bonferroni’s
correction was applied. The transmitted/non-transmitted and
overrepresentation/underrepresentation relationship of the allele
revealed consistent risk of the minor C allele of the initial marker
SNP (rs10491817) in each stage sample. The significant SNPs on
the ELAVL2 gene showed no deviation from Hardy-Weinberg
disequilibrium (based on the data from independent parents in the
Chinese sample set).
Quantitative RT-PCR in postmortem brains from
schizophrenia
The identification of ELAVL2 as a susceptibility gene for
schizophrenia in both Japanese and Chinese cohorts led us to
examine whether the expression levels of the gene are altered in
the postmortem brains of patients with schizophrenia. In addition,
the accumulating lines of evidence show that schizophrenia and
bipolar disorder partly share common susceptibility genes or
genetic pathways. We performed real-time quantitative RT-PCR
assays for mRNA levels of the gene in the dorsolateral prefrontal
cortex (DLPFC: Brodmann’s area 46) of schizophrenia, bipolar
disorder and control brains.
However, the experiments showed that the expression levels of
ELAVL2 were not different among brains from schizophrenics,
bipolar disorder patients and control subjects (Figure 4). We did
not examine the allele-specific expression levels of the transcript
because the minor allele (C) frequency is very low (0.056) in
Caucasian (from which the postmortem brains are derived)
according to the HapMap database (http://hapmap.ncbi.nlm.
nih.gov/).
Figure 1. A quantile-quantile (QQ) plot for association results
of the first-stage analysis. The empirical and theoretical distribu-
tions are shown as dots and line, respectively.
doi:10.1371/journal.pone.0020468.g001
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We performed a GWAS, a follow-up replication study and a
gene-centric dense mapping to identify susceptibility genes and risk
variants for schizophrenia in Japanese and Chinese populations. A
novel candidate gene has emerged from our staged association
analyses.
ELAVL2 [(embryonic lethal, abnormal vision, Drosophila)-like
2], also known as Hu antigen B (HuB) or Hel-N1, belongs to the
RNA-binding Hu (Elavl) protein family. In mammals, the family
consists of four highly conserved members that include the
ubiquitously expressed ELAVL1 (HuA, HuR) and the neuronal-
specific ELAVL2 (HuB, Hel- N1), ELAVL3 (HuC, ple21) and
ELAVL4 (HuD) [10,11,12,13,14]. Neuronal Elavl proteins
(nELAVL; ELAVL2, ELAVL3 and ELAVL4) have been identi-
fied as splicing regulators in neuron-like cells, and are likely to
exert critical posttranscriptional control as key inducers of
programmed neuronal differentiation and function in the
mammalian nervous system [15,16]. Given their role in neuronal
differentiation and plasticity, nELAVL proteins including
ELAVL2 could be potential candidates for neurodegenerative
and psychiatric diseases. Indeed, recent studies implicate ELAVL4
as a Parkinson’s disease susceptibility gene [17,18]. Noteworthy,
the altered expression of GAP43, one of known targets of ELAVL4,
is reported in the frontal cortices and the hippocampus of patients
with schizophrenia [19,20,21,22,23]. Although their relevance to
schizophrenia pathogenesis is still awaiting clarification, they are
worthy of further investigation.
In this work, we have attempted to minimize several limitations
often plaguing association studies in psychiatry. Firstly, to
minimize population stratification and genetic heterogeneity, we
have focused on trio samples of Japanese descent at the first stage.
Secondly, we conducted a replication study for significant SNPs
using case-control samples from the same Japanese population but
an independent sample set at the second stage. Finally, to confirm
the association in an ethnically close but different population, we
analyzed patient-parents trios/quads of Chinese descent at the
third stage. In this stage, to achieve greater coverage of genetic
variations for the survived gene, we performed gene-centric
analysis by selecting 56 tag SNPs throughout the entire region of
the gene (150 kb).
However, several limitations must be considered. We have
not achieved sufficient SNP coverage in the first stage of this
study, and the number of samples is modest to detect small to
medium effect of a disease-associated gene at genome-wide
significance level. When Bonferroni’s correction was applied,
the significant p value was 5.10610
27 for multiple tests of
97,963 SNPs (=0.05/97,963). The most significant p value in
the first stage analysis (p=6.11 610
26) loses significance after
conservative correction. In addition, a small number of genuine
causal variants will be buried within a larger number of SNPs
with nominal associations. Therefore, the current study will
require a follow-up analysis to distinguish the small number of
genuine causal variants from the high proportion of SNPs with
false-positive associations. The ELAVL2 gene showed a nominal
significance at each stage. However, the initial marker SNP in
Japanese population (rs10491817) was not significant in
Chinese population (p=0.082). This may reflect the allelic
heterogeneity of the gene, because the significant markers in
both populations were not in tight linkage disequilibrium
(Figures S1, S2). In this context, the gene warrants further
investigation.
Figure 2. Results of whole genome association scan for Japanese trio samples. A Manhattan plot is shown. SNPs from each chromosome
are represented by different colors and ordered by physical positions.
doi:10.1371/journal.pone.0020468.g002
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schizophrenia in Japanese population [1]. In the study, the
strongest associations were observed at rs12218361 mapped near
the 39 end of the OAT (a gene for ornithine aminotransferase) on
10q26.13 and rs11895771 mapped within the SULT6B1 (a gene
for sulfotransferase family, cytosolic, 6B, member 1) on 2p22.2
(p=7.2610
28 and p=6.2610
26, respectively). No significant
associations for those genes were observed in this study. However,
it is noteworthy that the two Japanese studies gave the same gene
of nominal significance, C6orf105 (Table 1). This putative gene is
reported as a candidate for non-syndromic oral clefts [24], but its
exact function is unknown.
Recent studies show suggestive evidence of association of
multiple GABA-related genes with schizophrenia [25,26]. One
of the benefits obtained from GWAS is that we can examine
whether a subset of genes categorized into some signaling pathway
are involved in the pathogeneses of disease, beyond single genes
[27]. We pursued this issue using the first-stage GWAS dataset and
unveiled the accumulation of association signals from genes of
GABAergic pathways in schizophrenia. Association signature on
GABA-related loci was identified across several human chromo-
somes, which is particularly highlighted on chromosome 5q34
(Figure S3). However, most of the SNPs in and around GABA-
related genes associated with schizophrenia in our first-stage
dataset were not confirmed in the second-stage samples. Only
rs10515831, which lies 90 kb downstream of GABRB2,4 7 k b
upstream of GABRA6 and 209 kb upstream of GABRA1 on 5q34,
showed a nominal significant association with the disease in the
second-stage analysis (p=0.033). This may be due to weak genetic
contributions of these genes in Japanese, suggesting the necessity of
a much larger number of second-stage samples.
In summary, we provided a suggestive evidence for the
contribution of ELAVL2 to the pathogenesis of schizophrenia, in
both Japanese and Chinese populations. This prioritized gene
deserves further evaluation to improve the understanding of
schizophrenia genetics.
Materials and Methods
Samples
A three-stage analysis was performed by using two independent
Japanese cohorts and an ethnically close Chinese population. In
the first stage, 120 patient-parents trio samples from Japanese
schizophrenia pedigrees (360 members) were analyzed. In the
second stage, case–control samples consisted of 1,012 unrelated
individuals (506 schizophrenia patients, mean age 49.2613.0
years; 506 age- and sex-matched controls, mean age 49.2613.0
years). In the third stage, Chinese sample consisted of 293
pedigrees (1,163 subjects: nine trios and 284 quads) collected by
the NIMH initiative (http://nimhgenetics.org/). For the Japanese
samples, all the subjects resided in central Japan. Consensual
diagnoses were made by at least two experienced psychiatrists
according to DSM-IV criteria. Written informed consent was
obtained from all the participants, after the provision and an
Table 1. The top 20 signals in the two-stage association analyses.
RANK SNP ID Position p value Gene HWE p value
1st stage 2nd stage Control Case
1 rs10491817 9p21.3 0.00649 0.00087 ELAVL2 0.576 0.879
2 rs10507559 13q14.2 0.00933 0.00094 0.498 0.382
3 rs9296021 6p21.32 0.01030 0.00158 C6orf10 0.240 0.035
4 rs10497106 2q23.3 0.00091 0.00181 FMNL2 0.159 0.280
5 rs1899264 2p12 0.02010 0.00240 0.679 0.972
6 rs950651 5p15.32 0.00014 0.00299 0.713 0.256
7 rs1449531 3p24.3 0.00024 0.00299 0.439 0.531
8 rs7970954 12p12.1 0.00511 0.00329 IFLTD1 0.900 0.021
9 rs488212 11q22.3 0.01590 0.00386 0.310 0.658
10 rs7695870 4q32.1 0.00953 0.00419 GRIA2 0.843 0.975
11 rs660647 11q22.3 0.01510 0.00530 0.345 0.801
12 rs10517668 4q32.1 0.00376 0.00549 0.875 0.682
13 rs2289965 11p15.1 0.00286 0.00678 IGSF22 0.273 0.711
14 rs2292101 3p25.2 0.01140 0.00679 PPARG 0.817 0.550
15 rs2235394 6p24.1 0.01110 0.00697 C6orf105 0.306 0.556
16 rs10496761 2q22.1 0.03250 0.00912 0.099 0.678
17 rs1048076 6p21.1 0.00225 0.00945 ENPP4 0.974 0.876
18 rs348116 5p15.2 0.00270 0.00952 0.207 0.918
19 rs10505845 12p12.2 0.00838 0.01010 0.392 0.868
20 rs3106653 2q24.1 0.00465 0.01194 KCNJ3 0.710 0.199
Rank is ordered according to the results of the second-stage analysis.
SNP information is listed based on UCSC Feb. 2009 (http://genome.ucsc.edu/).
P values of the 1
st stage are calculated by Transmission Disequilibrium Test (TDT).
P values of the 2
nd stage are calculated by Fisher’s exact test.
HWE: Hardy Weinberg Equilibrium. Departures from the assumption of HWE are evaluated based on the data from the 2
nd stage case-control samples.
doi:10.1371/journal.pone.0020468.t001
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the current study consist of all such patients with schizophrenia
who are in a remission/stable chronic state and possess the ability
to agree to join the research. This study was approved by the
Ethics Committee of RIKEN, and conducted according to the
principles expressed in the Declaration of Helsinki.
First-stage analysis
The first-stage GWAS was performed using Affymetrix
GeneChip Mapping 100 K microarrays (Affymetrix, Santa Clara,
CA) following the manufacturer’s protocol. Genotype data were
analyzed with the GeneSpring GT (Varia) 2.0 software package
developed by Agilent Technologies (Santa Clara, CA). Transmis-
sion disequilibrium test was performed using the R program
(http://www.r-project.org). We set a liberal first-stage significance
level to increase the potential to detect associated genes with small
effects in the subsequent stage analyses: (i) p value,0.01, and (ii) p
value,0.05 when SNPs are located in candidate chromosomal
regions detected in the meta-analysis of schizophrenia linkage
studies [9] or in the reported linkage regions of Japanese
population [8]. We used the Haploview 4.2 to create a Manhattan
plot of p values from GWAS study (http://www.broadinstitute.
org/haploview). A QQ plot of p values from GWAS was created
using R scripts provided by Diabetes Genetics Initiative (http://
www.broadinstitute.org/science/projects/diabetes-genetics-initia-
tive/plotting-genome-wide-association-results). The data obtained
in this study have been deposited into the NCBI’s Gene
Expression Omnibus [28] and are accessible through GEO Series
accession number GSE27923 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE27923).
Second-stage analysis
In the second stage, genotyping was performed using Illumina
(San Diego, CA), through the use of their Integrated BeadArray
System. We supplied Illumina with 96-well barcoded DNA
microtiter plates containing 1,012 samples of DNA (4 mg each)
quantified with Pico Green to be 100 ng/ml. Assay quality was as
follows: sample success rate of 100%, locus success rate of 97.40%,
Figure 3. Genomic structure of ELAVL2 and gene-centric association analysis. Genomic structure and locations of genetic markers in and
around ELAVL2 are shown, with chromosomal positions according to the human genome database (http://genome.ucsc.edu/) on the top. Exons of
the gene are denoted by boxes. The negative logarithm of p value for association is plotted as a function of chromosomal positions of SNP markers.
Bold line indicates p value of ,0.05.
doi:10.1371/journal.pone.0020468.g003
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genotyping concordance of 99.93%. These results indicate that
genotyping was highly accurate and reproducible in this study.
Statistical analysis of allelic association was performed using the R
program.
Gene-centric association study
In a gene-centric association study, SNP genotyping was
performed using the TaqMan system (Applied Biosystems, Foster
City, CA) following the manufacturer’s recommendation. PCR
was performed using an ABI 9700 thermocycler, and fluorescent
signals were analyzed on an ABI 7900HT Fast real-time PCR
System using Sequence Detection Software (SDS) v2.3 (Applied
Biosystems). TagSNPs were selected using the ldSelect software
(http://droog.gs.washington.edu/ldSelect.html) based on their r
2
values of 0.8 as a cut-off point to capture genotype information.
We genotyped 56 tagSNPs located in and around the ELAVL2
gene in the stage III. The genetic association was evaluated using
the Family-Based Association Test (FBAT) program (v2.0.3,
http://www.biostat.harvard.edu/,fbat/).
Brain tissues and quantitative RT-PCR
RNA from the dorsolateral prefrontal cortex (Brodmann’s area
46) was obtained from the Stanley Medical Research Institute
(http://sncid.stanleyresearch.org/) [29,30]. Brain samples were
taken from 35 schizophrenics [26 males, 9 females; mean 6 SD
age, 42.668.5 years; postmortem interval (PMI), 31.4615.5 h;
brain pH, 6.560.2], 35 bipolar disorder patients (17 males, 18
females; mean 6 SD age, 45.3610.5 years; PMI, 37.9618.3 h;
brain pH, 6.460.3), and 35 controls (26 males, 9 females; mean 6
SD age, 44.267.6 years; PMI, 29.4612.9 h; brain pH, 6.660.3).
Diagnoses were made in accordance with DSM-IV criteria. There
were no significant demographic differences between the schizo-
phrenia, bipolar and control brains, in terms of age, postmortem
interval and sample pH. All the patients with schizophrenia were
administered with anti-psychotics. Quantitative RT-PCR analysis
was conducted using an ABI7900HT Fast Real-Time PCR System
(Applied Biosystems). TaqMan probes and primers for ELAVL2
and GAPDH (an internal control) were Assay-on-Demand
TM or
Assay-by-Design
TM gene expression products (Applied Biosys-
tems). All the quantitative RT-PCR reactions were performed in
triplicate, based on a standard curve method. The Mann-Whitney
U test (two–tailed) was used to evaluate significant changes in
target gene expression levels.
Supporting Information
Table S1 Replication in Japanese case-control samples
(autosomes). SNP information is based on the UCSC database
(http://genome.ucsc.edu/). P values of the 1st stage analysis are
calculated by Transmission Disequilibrium Test (TDT). P values
of the 2nd stage analysis are calculated by Fisher’s exact test.
HWE: Hardy Weinberg Equilibrium. Departures from the
assumption of HWE are evaluated based on the data from the
2nd stage case-control samples.
(XLS)
Table S2 Replication in Japanese case-control samples
(chromosome X). SNP information is based on the UCSC
database (http://genome.ucsc.edu/). P values of the 1st stage
analysis are calculated by Transmission Disequilibrium Test
(TDT). P values of the 2nd stage analysis are calculated by
Fisher’s exact test.
(XLS)
Figure S1 Linkage disequilibrium between markers in
Chinese population. Linkage disequilibrium (LD) between
markers constructed by the Haploview program is shown (based
on the data from independent parents in the Chinese sample set).
The number in each cell represents the LD parameter r
2 (6100).
Each cell is painted with graduated color relative to the strength of
linkage disequilibrium between markers. The rs numbers are SNP
I.D. in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/
snp). The significant SNPs and the genomic region surrounding
these SNPs were shown in red and a red pentagon, respectively.
(TIF)
Figure S2 Linkage disequilibrium between markers in
Japanese population. Linkage disequilibrium (LD) between
markers constructed by the Haploview program using the data
from HapMap database is shown (http://hapmap.ncbi.nlm.nih.
gov/). The number in each cell represents the LD parameter r
2
(6100). Each cell is painted with graduated color relative to the
strength of linkage disequilibrium between markers. The rs
numbers are SNP I.D. in the NCBI SNP database (http://www.
ncbi.nlm.nih.gov/snp). The significant SNPs and the genomic
region surrounding these SNPs were shown in red and a red
pentagon, respectively.
(TIF)
Figure S3 Association signals on chromosome 5q GA-
BAA receptor subunit gene cluster. The chromosome 5q risk
locus contains a cluster of GABAA receptor subunit genes,
GABRB2, GABRA6, GABRA1, GABRG2 and GABRP. Significant
SNPs (p,0.05) and the corresponding genes are shown in red.
(TIF)
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